Metylfenidat Medical Valley (Methylphenidate)
Extended-release tablets for ADHD treatment in children and adults
Metylfenidat Medical Valley contains methylphenidate hydrochloride, a central nervous system (CNS) stimulant used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older and in adults. This extended-release formulation delivers medication over approximately 12 hours, requiring only one dose per morning. It is prescribed as part of a comprehensive treatment program that includes psychological, educational, and social support.
Quick Facts
Key Takeaways
- Metylfenidat Medical Valley is an extended-release methylphenidate tablet taken once daily in the morning for ADHD management in patients aged 6 and older.
- The tablet must be swallowed whole — never chewed, split, or crushed — to maintain its extended-release mechanism over approximately 12 hours.
- Common side effects include headache, insomnia, and decreased appetite; serious cardiovascular events are rare but require monitoring.
- This medication must not be combined with MAO inhibitors, and caution is needed with antidepressants due to the risk of serotonin syndrome.
- Regular medical check-ups including blood pressure, heart rate, weight, and height monitoring are essential throughout treatment.
What Is Metylfenidat Medical Valley and What Is It Used For?
Metylfenidat Medical Valley contains methylphenidate hydrochloride as its active ingredient. Methylphenidate belongs to the class of central nervous system (CNS) stimulants and has been one of the most widely studied and prescribed medications for ADHD since the 1960s. The extended-release formulation uses an osmotic-controlled release oral delivery system (OROS) that provides a controlled, gradual release of the medication over approximately 10 to 12 hours after ingestion.
The primary indication for Metylfenidat Medical Valley is the treatment of Attention Deficit Hyperactivity Disorder (ADHD), a neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with daily functioning. ADHD affects approximately 5–7% of children and 2.5–4% of adults worldwide, according to epidemiological studies referenced by the World Health Organization (WHO) and the European Medicines Agency (EMA).
How Does It Work?
Methylphenidate works by blocking the reuptake of the neurotransmitters dopamine and norepinephrine into presynaptic neurons. This increases the concentration of these chemical messengers in the synaptic cleft, particularly in prefrontal cortex regions that are underactive in people with ADHD. The result is improved attention span, enhanced concentration, and reduced impulsive behavior.
Unlike immediate-release methylphenidate formulations that require multiple doses throughout the day, the extended-release technology in Metylfenidat Medical Valley delivers an initial dose within the first hour, followed by a gradual ascending release pattern that mimics the effect of taking multiple immediate-release doses. This provides consistent symptom control throughout the school or work day.
Part of a Comprehensive Treatment Program
Metylfenidat Medical Valley is not intended as a standalone treatment. International guidelines from NICE (National Institute for Health and Care Excellence), the European ADHD Guidelines Group, and the American Academy of Pediatrics all recommend that pharmacotherapy for ADHD should be part of a multimodal approach that typically includes:
- Psychological therapy — cognitive behavioral therapy (CBT), psychoeducation
- Educational support — classroom accommodations, specialized teaching strategies
- Social skills training — peer relationship building, behavioral management
- Parent/caregiver training — behavioral management techniques
Medication should only be initiated after non-pharmacological interventions have been considered. For children and adolescents with moderate to severe ADHD, methylphenidate is recommended as the first-line pharmacological option by NICE and EMA guidelines. For adults who were not previously treated, a specialist should confirm that ADHD symptoms have been present since childhood before starting treatment.
ADHD is a recognized neurodevelopmental condition — not a reflection of intelligence or character. Many children and adults with ADHD struggle with tasks that require sustained attention, organization, or impulse control. While there is no cure for ADHD, effective management through a combination of medication and behavioral support can significantly improve daily functioning and quality of life.
What Should You Know Before Taking Metylfenidat Medical Valley?
Contraindications
Metylfenidat Medical Valley must not be used if you or your child:
- Are allergic to methylphenidate or any of the inactive ingredients
- Have thyroid problems (hyperthyroidism)
- Have increased pressure in the eye (glaucoma)
- Have a tumor of the adrenal gland (pheochromocytoma)
- Have an eating disorder such as anorexia nervosa
- Have very high blood pressure or narrowing of blood vessels
- Have or have had serious heart problems, including heart attack, irregular heartbeat, heart failure, or congenital heart disease
- Have had cerebrovascular problems such as stroke, brain aneurysm, or vasculitis
- Are currently taking, or have taken within the past 14 days, a monoamine oxidase inhibitor (MAO inhibitor) for depression
- Have psychopathic or borderline personality disorder, psychotic symptoms, or schizophrenia
- Have severe depression with suicidal thoughts, or mania
Never take Metylfenidat Medical Valley if you are currently taking or have taken a monoamine oxidase inhibitor (MAOI) within the last 14 days. This combination can cause a dangerous, sudden increase in blood pressure (hypertensive crisis) that can be life-threatening.
Warnings and Precautions
Talk to your doctor before taking Metylfenidat Medical Valley if you or your child:
- Have liver or kidney problems
- Have difficulty swallowing or problems swallowing whole tablets
- Have a narrowing or obstruction of the gastrointestinal tract or esophagus
- Have had seizures (epilepsy) or abnormal electroencephalogram (EEG) findings
- Have ever misused or been dependent on alcohol, prescription medications, or recreational drugs
- Have high blood pressure or any heart condition not listed above
- Have tics or Tourette syndrome, or a family history of tics
- Have mental health conditions including bipolar disorder, aggressive behavior, hallucinations, paranoia, or depression
Your doctor will perform a thorough evaluation before starting treatment. This assessment typically includes checking your current medications, family medical history (including any unexplained sudden deaths), cardiovascular health, and mental health status. For adults not previously treated, the doctor may refer you to a cardiologist for a cardiovascular assessment.
Monitoring During Treatment
Regular check-ups are required throughout treatment, typically at least every 6 months. These include:
- Blood pressure and heart rate measurement
- Height and weight monitoring (especially in children)
- Appetite assessment
- Mood and mental health evaluation
- Assessment of whether the medication is still needed (treatment holidays may be recommended)
If you or your child experience blurred vision or other visual disturbances during treatment, contact your doctor promptly. In boys and adolescents, prolonged or painful erections (priapism) may occur rarely — seek immediate medical attention if an erection lasts more than 2 hours.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medication. Available data does not suggest an overall increased risk of birth defects. However, a small increase in the risk of cardiac malformations during the first trimester cannot be entirely excluded. Your doctor will weigh the benefits of continued treatment against potential risks.
Methylphenidate passes into breast milk. If you are breastfeeding or planning to breastfeed, your doctor will decide whether you should breastfeed while taking this medication or whether an alternative approach is appropriate.
Driving and Operating Machinery
Methylphenidate may cause dizziness, blurred vision, or difficulty focusing, particularly at the start of treatment or when the dose is changed. If you experience these symptoms, avoid driving, cycling, or operating heavy machinery until the effects have resolved. Discuss any concerns about driving with your doctor.
Drug Testing
Methylphenidate may produce positive results on drug screening tests for amphetamines. If you are required to undergo drug testing (for employment, sports, or other purposes), inform the testing authority that you are taking this prescribed medication.
Metylfenidat Medical Valley contains lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially sodium-free.
How Does Metylfenidat Medical Valley Interact with Other Drugs?
Methylphenidate can interact with a variety of other medications, either reducing their effectiveness or increasing the risk of adverse effects. It is crucial to inform your prescriber about all medications you are currently taking, including over-the-counter medicines, herbal supplements, and vitamins. The following table summarizes the most clinically significant drug interactions:
Major Interactions
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| MAO inhibitors (e.g., phenelzine, tranylcypromine, moclobemide) | Risk of hypertensive crisis — potentially life-threatening sudden blood pressure increase | Contraindicated. Do not use within 14 days of MAO inhibitor therapy. |
| SSRIs (e.g., fluoxetine, sertraline, paroxetine) | Increased risk of serotonin syndrome (confusion, sweating, tremor, rapid heartbeat) | Use with caution. Monitor closely for serotonin syndrome symptoms. |
| SNRIs (e.g., venlafaxine, duloxetine) | Increased risk of serotonin syndrome | Use with caution. Seek immediate medical help if symptoms develop. |
| Tricyclic antidepressants (e.g., amitriptyline, imipramine) | Methylphenidate may increase plasma levels of tricyclics; risk of serotonin syndrome | Monitor closely. Dose adjustment of the antidepressant may be needed. |
Other Important Interactions
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| Antihypertensives (blood pressure medications) | Methylphenidate may reduce the effectiveness of blood pressure medications | Monitor blood pressure regularly. Dose adjustment may be required. |
| Anticoagulants (e.g., warfarin) | Methylphenidate may inhibit metabolism of warfarin, increasing bleeding risk | Monitor INR closely when starting or stopping methylphenidate. |
| Antiepileptic drugs (e.g., phenytoin, phenobarbital) | Methylphenidate may increase plasma levels of antiepileptics | Monitor antiepileptic drug levels and adjust dose if necessary. |
| Dopaminergic drugs (e.g., levodopa for Parkinson's disease) | Potential additive dopaminergic effects | Use with caution under specialist supervision. |
| Cough/cold medicines containing pseudoephedrine | May increase blood pressure (combined sympathomimetic effects) | Consult your pharmacist before purchasing any cough/cold medicines. |
| Antipsychotics | May counteract the effects of methylphenidate | Use only under specialist supervision with careful monitoring. |
Alcohol
Do not consume alcohol while taking Metylfenidat Medical Valley. Alcohol can worsen the side effects of methylphenidate, particularly drowsiness and impaired judgment. Be aware that some foods and medications may contain alcohol.
Surgery and Anesthesia
Inform your surgeon and anesthesiologist that you are taking methylphenidate if you are scheduled for any surgical procedure. Methylphenidate should not be taken on the day of surgery if certain types of anesthetics (halogenated anesthetics) are to be used, as there is a risk of sudden blood pressure elevation during the operation.
What Is the Correct Dosage of Metylfenidat Medical Valley?
Always take Metylfenidat Medical Valley exactly as prescribed by your doctor. The dose is individualized based on clinical response and tolerability. The general principle is to start at the lowest available dose and titrate upward gradually to find the minimum effective dose for each patient.
How to take the tablet: Take one tablet once daily in the morning with a glass of water. The tablet must be swallowed whole — do not chew, split, or crush it, as this will destroy the extended-release mechanism and may lead to excessive drug release. The tablet can be taken with or without food. You may notice the empty tablet shell in your stool; this is normal and does not mean the medication has not been absorbed.
Children and Adolescents (6 Years and Older)
Children — Starting Treatment
Starting dose: 18 mg once daily in the morning
Titration: The doctor may increase the dose by 18 mg increments, no more frequently than once per week
Maximum daily dose: 54 mg
Note: Metylfenidat Medical Valley is not indicated for children under 6 years of age.
Adults
Adults — Previously Treated
If you have previously taken methylphenidate as a child or adolescent, the same daily dose (mg/day) may be used as a starting point. Your doctor will review and adjust as needed.
Adults — Starting Treatment for the First Time
Starting dose: 18 mg once daily in the morning
Titration: Gradual increase by 18 mg per week as needed
Maximum daily dose: 72 mg
| Patient Group | Starting Dose | Titration | Maximum Dose |
|---|---|---|---|
| Children (6–12 years) | 18 mg/day | +18 mg/week | 54 mg/day |
| Adolescents (13–17 years) | 18 mg/day | +18 mg/week | 54 mg/day |
| Adults (new to treatment) | 18 mg/day | +18 mg/week | 72 mg/day |
| Adults (previously treated) | Previous dose | Adjusted as needed | 72 mg/day |
Missed Dose
If you forget to take your dose, do not take a double dose to make up for it. Simply skip the missed dose and take the next dose at the usual time the following morning. Taking methylphenidate later in the day may interfere with sleep.
Overdose
If you or your child has taken too much Metylfenidat Medical Valley, or if a child has accidentally ingested the medication, contact your local emergency services or poison control center immediately. Medical treatment may be required.
Signs of overdose may include: nausea, agitation, tremors, uncontrolled movements, muscle twitching, seizures (which may be followed by coma), feelings of euphoria, confusion, hallucinations (seeing, feeling, or hearing things that are not real), sweating, flushing, headache, high fever, changes in heart rate (slow, fast, or irregular), high blood pressure, dilated pupils, and dry mucous membranes.
Stopping Treatment
Do not stop taking Metylfenidat Medical Valley suddenly without consulting your doctor. Abrupt discontinuation may cause ADHD symptoms to return or may lead to withdrawal effects such as depression. Your doctor may choose to gradually reduce the daily dose before discontinuing treatment completely.
Long-Term Treatment
Metylfenidat Medical Valley does not need to be taken indefinitely. If you or your child have been taking it for more than one year, your doctor will periodically pause treatment (often during a school break) to assess whether the medication is still needed. This “drug holiday” helps determine if symptoms have improved sufficiently to manage without medication. If there is no improvement after one month of treatment, your doctor may recommend an alternative approach.
What Are the Side Effects of Metylfenidat Medical Valley?
Like all medicines, Metylfenidat Medical Valley can cause side effects, although not everyone experiences them. Most people find that methylphenidate helps them significantly, and many side effects are mild and tend to improve as the body adjusts to the medication. Your doctor will discuss these potential effects with you before starting treatment.
Seek Immediate Medical Attention
Contact emergency medical services immediately if you or your child experience any of the following:
- Signs of a severe allergic reaction: rash, itching, swelling of the face, lips, tongue, or throat, difficulty breathing
- Unexplained fainting, chest pain, or shortness of breath (possible signs of heart problems)
- Suicidal thoughts or feelings
- Seeing, feeling, or hearing things that are not real (hallucinations)
- Seizures or convulsions
- Prolonged, painful erection lasting more than 2 hours
- Sudden numbness or weakness, confusion, difficulty speaking, or severe headache (possible signs of stroke)
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Headache
- Nervousness
- Difficulty sleeping (insomnia)
Common
May affect up to 1 in 10 people
- Decreased appetite, weight loss
- Palpitations (irregular heartbeat), increased heart rate (tachycardia), high blood pressure
- Mood changes, mood swings, personality changes, aggression, irritability
- Dizziness, tremor, hyperactivity, uncontrollable movements
- Dry mouth, nausea, stomach pain, vomiting, diarrhea
- Joint pain, muscle tension, muscle cramps
- Blurred vision
- Excessive sweating
- Itching, rash, hives
- Fatigue, sleepiness
- Cough, sore throat, upper respiratory infection, sinusitis
- Teeth grinding (bruxism)
- Panic feelings, tingling or numbness in the skin
- Erectile dysfunction, decreased libido
- Hair loss or thinning
- Elevated liver enzyme (alanine aminotransferase)
Uncommon
May affect up to 1 in 100 people
- Suicidal thoughts or feelings
- Hallucinations (seeing, feeling, or hearing things that are not real)
- Tourette syndrome (uncontrolled speech or movements)
- Allergic reactions (rash, itching, facial swelling, difficulty breathing)
- Dry eyes, constipation, chest discomfort
- Blood in urine, increased urination frequency
- Trembling, shortness of breath
- Elevated liver values
- Anger, restlessness, excessive talkativeness
Rare
May affect up to 1 in 1,000 people
- Mania (feeling unusually elated, overactive, or uninhibited)
- Disorientation or confusion
- Visual disturbances, double vision
- Breast enlargement in males
- Skin redness, raised red skin rashes
- Obsessive-compulsive symptoms
- Changes in sexual desire
Very Rare
May affect up to 1 in 10,000 people
- Heart attack, sudden cardiac death
- Suicide attempt
- Seizures (convulsions, epileptic seizures)
- Peeling or blistering skin
- Cerebral vasculitis (inflammation of blood vessels in the brain)
- Neuroleptic malignant syndrome (sudden high fever, very high blood pressure, severe muscle rigidity)
- Decreased blood cell counts (red cells, white cells, platelets)
- Abnormal liver function, including liver failure
- Raynaud phenomenon (numbness in fingers and toes with color changes)
Effects on Growth in Children
When used for more than one year, methylphenidate may slow growth in some children. This affects fewer than 1 in 10 children and may include reduced weight gain and slower height growth. Your doctor will carefully monitor your child's height, weight, and appetite throughout treatment. If growth is not progressing as expected, the doctor may temporarily pause treatment to allow catch-up growth.
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority. By reporting side effects, you contribute to improving medication safety information.
How Should You Store Metylfenidat Medical Valley?
Proper storage is essential to maintain the effectiveness and safety of your medication:
- Keep out of the sight and reach of children. As a controlled substance, this medication must be stored securely.
- Keep the container tightly closed to protect against moisture. The tablets are moisture-sensitive.
- No special temperature requirements — store at room temperature.
- Do not use after the expiry date printed on the label and carton after “EXP.” The expiry date refers to the last day of the indicated month.
- Do not eat the desiccant containers found inside the jar. These small containers keep the tablets dry and are not intended for consumption.
Do not dispose of medications via the household waste or down the drain. Ask your pharmacist how to dispose of medications you no longer use. These measures help protect the environment and prevent accidental ingestion.
What Does Metylfenidat Medical Valley Contain?
Active Ingredient
The active substance is methylphenidate hydrochloride. Each tablet contains 18 mg, 27 mg, 36 mg, 45 mg, or 54 mg of methylphenidate hydrochloride.
Inactive Ingredients (Excipients)
The tablets contain the following additional components:
- Tablet core: Hypromellose, macrogol, succinic acid, magnesium stearate, sodium chloride, anhydrous colloidal silicon dioxide, black iron oxide (E172)
- Film coating: Cellulose acetate, macrogol
- Surface treatment: Hypromellose, macrogol, phosphoric acid (for pH adjustment)
- Color coating: Lactose monohydrate, hypromellose, triacetin, titanium dioxide (E171), yellow iron oxide (E172) (18 mg), red iron oxide (E172) (18 mg, 27 mg, 54 mg), black iron oxide (E172) (27 mg), indigotine (E132) (45 mg)
Tablet Appearance
| Strength | Color | Shape & Size |
|---|---|---|
| 18 mg | Yellow | Round, biconvex, ~9 mm diameter, small hole on one side |
| 27 mg | Grey | Round, biconvex, ~9 mm diameter, small hole on one side |
| 36 mg | White | Round, biconvex, ~10 mm diameter, small hole on one side |
| 45 mg | Blue | Round, biconvex, ~10 mm diameter, small hole on one side |
| 54 mg | Pink | Round, biconvex, ~10 mm diameter, small hole on one side |
The small hole visible on one side of each tablet is a normal feature of the OROS delivery system — it is the opening through which the medication is released as the tablet passes through your digestive system.
Packaging
Metylfenidat Medical Valley is supplied in plastic jars with child-resistant closures. Each jar contains two desiccant containers to keep the tablets dry. Available pack sizes include 30 tablets (all strengths), 60 tablets (2×30), and 90 tablets (3×30) for the 18 mg, 27 mg, 36 mg, and 54 mg strengths. Not all pack sizes may be marketed in your country.
Frequently Asked Questions
Metylfenidat Medical Valley is an extended-release methylphenidate tablet used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older and in adults. It is prescribed as part of a comprehensive treatment program that typically includes psychological, educational, and social therapy. The extended-release mechanism provides symptom control for approximately 12 hours with a single morning dose.
Take one tablet once daily in the morning with a glass of water. The tablet must be swallowed whole — never chewed, split, or crushed, as this will destroy the extended-release mechanism. It can be taken with or without food. The empty tablet shell may appear in your stool, which is completely normal and means the medication has already been absorbed.
The most common side effects (affecting more than 1 in 10 people) are headache, nervousness, and difficulty sleeping (insomnia). Common side effects (up to 1 in 10) include decreased appetite, weight loss, dizziness, nausea, dry mouth, elevated heart rate, and mood changes. Most side effects are mild to moderate and tend to improve as the body adjusts to the medication. Contact your doctor if side effects are persistent or bothersome.
Available data does not suggest an overall increased risk of birth defects. However, a small increase in the risk of cardiac malformations cannot be excluded when used during the first trimester. Consult your doctor before using methylphenidate if you are pregnant, think you may be pregnant, or are planning to become pregnant. Your doctor will evaluate the benefits and risks to decide whether the medication should continue. Methylphenidate also passes into breast milk, so discuss breastfeeding with your doctor.
If you miss a dose of Metylfenidat Medical Valley, do not take a double dose to compensate. Skip the missed dose and take the next dose at the regular time the following morning. Taking methylphenidate later in the day may cause difficulty falling asleep at night.
Methylphenidate is classified as a controlled substance because it has potential for misuse and dependence. However, when taken as prescribed under medical supervision for the treatment of ADHD, the risk of developing addiction is considered low. The extended-release formulation further reduces misuse potential compared to immediate-release forms, as the medication is released gradually over 12 hours rather than all at once. Always inform your doctor if you have a history of substance misuse.
References
- European Medicines Agency (EMA). Summary of Product Characteristics: Methylphenidate hydrochloride prolonged-release tablets. EMA/CHMP. Updated 2025.
- National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. Updated March 2024.
- Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727-738.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Methylphenidate included for ADHD management.
- Faraone SV, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews. 2021;128:789-818.
- Storebø OJ, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews. 2018;5:CD012069.
- American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents. Pediatrics. 2019;144(4):e20192528.
- British National Formulary (BNF). Methylphenidate hydrochloride. NICE Evidence Services. 2025.
- U.S. Food and Drug Administration (FDA). Methylphenidate Hydrochloride Extended-Release Tablets – Prescribing Information. Updated 2024.
Editorial Team
Medical Review Board
Board-certified specialists in psychiatry and neuropharmacology with expertise in ADHD treatment across the lifespan.
Clinical Pharmacology
Licensed clinical pharmacologists specializing in psychotropic medications, drug interactions, and pharmacovigilance.
Content Quality
Medical writers and editors who ensure accuracy, readability, and adherence to GRADE evidence standards.
Accessibility & UX
WCAG 2.2 AAA compliance specialists ensuring all medical content is accessible to users with disabilities.
Evidence Standard: All content follows the GRADE framework. Drug information is cross-referenced against EMA SmPC data, FDA prescribing information, BNF monographs, and WHO essential medicines guidelines. No commercial funding is accepted.